TACSTD2 and cancer: Similarly, some of our heralded anti-cancer therapeutics, such as anti-PDL1 [105,106,107], anti-HER2 [35], anti-NECTIN4 [108,109], and anti-TROP2 [36,37], are also anti-CSC drugs that can be, or have already been, utilized in combination with anti-non-CSC treatments to maximize clinical outcomes.